November 2024, Shanghai — Riding the wave of deep integration between AI and life sciences, Shanghai LinZight Technology Co., Ltd., （LinZight Technology ）incubated by Tee Labs, was officially launched in Zhangjiang Science City, Shanghai. As a medical data application innovator driven by AI, LinZight aims to become a global leader in building intelligent healthcare ecosystems. The company is…

Recently, PoliaValve™, a polymer artificial heart valve independently developed by Tee Labs-incubated company Suzhou Hearthill Medical Technology Co., Ltd. (“Suzhou Hearthill Medical”), was successfully implanted in a 69-year-old male patient during an aortic valve replacement surgery performed by Professor Lu Fanglin’s team at the Department of Cardiovascular Surgery, Shanghai General Hospital, on September 13, 2024. One-month follow-up results show excellent performance…

July 25, 2024 – China’s Center for Drug Evaluation (CDE) announced that FS-8002, a bispecific antibody fusion protein targeting the tumor microenvironment independently developed by Fusion Bioscience (Shanghai) Biotechnology Co., Ltd. (a wholly-owned subsidiary of Huapu Biotechnology), has received clinical trial authorization for advanced solid tumors. Notably, the investigational new drug (IND) application for FS-8002 was…

June 11 – Gene therapy innovator  Innostellar Biotherapeutics Co.,Ltd announced the completion of its Series B+ funding round, led by Shanghai Healthcare Capital with participation from existing shareholder United Capital Investment. Founded in 2020, Innostellar Biotherapeutics focuses on developing and manufacturing innovative gene therapies. The company has established a scalable, GMP-compliant AAV manufacturing platform capable of producing…

Shanghai, China – The Zhangjiang Branch of the Shanghai Headquarter Enterprise Development Association (SHEDA) was formally inaugurated recently with a grand ceremony held at the Huisheng Center in Zhangjiang. Dr. Ni Lin, CEO of Tee Labs, was honored to be appointed as the Secretary General and Council Member of the SHEDA Zhangjiang Branch during the…

    Recently, Professor Yuan Junying, Foreign Member of the Chinese Academy of Sciences (CAS), Member of the U.S. National Academy of Sciences, and Director of the Center for Interdisciplinary Research in Biology and Chemistry, Shanghai Institute of Organic Chemistry(CAS) , gave an interview to Shanghai Media Group, sharing her pioneering work in the field of…

Tee Labs Incubatee: Full-Life Technologies Announces Clearance from FDA of IND Application for ²²⁵Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer.Heidelberg, Germany – May 30, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced it has received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration…

Global radiotherapeutics company Full-Life Technologies announces USD $47.3 million Series B financing, Prosperity7 Ventures jointly leads the round Shanghai, Gembloux, Belgium, and Heidelberg, Germany – Jan. 4, 2024 – Full-Life Technologies (“Full-Life”), a fully integrated global radiotherapeutics company, today announced the completion of $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities. The financing…

October 11, 2023 Pudong New Area published an article titled “Supporting Scientific Innovation from 0 to 1: Tee Labs Nurtures Biotech Startups”, recognizing Tee Labs’ contributions to advancing domestic pharmaceutical innovation. Since its establishment, Tee Labs has provided comprehensive support to biotech startups—including R&D facilities, corporate functions, integrated supply chain services, and funding. Within Tee…

Accelerating International Cooperation: Tee Labs and Mitsubishi Tanabe Partner to Support the Global Expansion of Chinese Biotech China’s pharmaceutical industry is advancing towards a deeper level of internationalization. Early-stage domestic biopharmaceutical companies are also actively accelerating the internationalization of their technologies, entering the global market, and exploring paths for global expansion. Recently, Tee Labs and…

On February 3, 2023, Structure Therapeutics, an incubated company of Tee Labs—a biopharmaceutical professional incubator located in Zhangjiang, Pudong, Shanghai—was listed on the Nasdaq Stock Market in the United States. Structure Therapeutics is a clinical-stage global biopharmaceutical company dedicated to developing novel oral therapeutics for a variety of chronic diseases. The company utilizes world-class proprietary…

On November 29, Full-Life Technologies (“Full-Life”), a Tee Labs Incubatee, announced the acquisition of Focus-X Therapeutics (“Focus-X”), a New Jersey, USA-based company developing targeted radiopharmaceuticals for the treatment of cancer based on its proprietary peptide engineering technology. The acquisition, valued at $245 million, is expected to close in the first quarter of 2023. Founded in…

The co-founder of Full-Life Technologies told R&D-based Medicine, “The range of targets that can be developed for RDCs (Radiopharmaceutical-Drug Conjugates) is not very limited. In theory, RDCs can pursue any target that ADCs can, and they also have the advantage of a ‘theranostic’ approach.” Driven by the dual forces of pharmaceutical giants and capital, Radiopharmaceutical-Drug…

  Following a review by the Shanghai Pudong New Area Science, Technology and Economic Commission, Tee Labs was officially recognized as an Innovative Incubator of Pudong New Area on August 11, 2022. Tee Labs and its incubated companies are now eligible to enjoy corresponding incentive policies. Since its official launch in September 2021, Tee Labs…

ShouTi Inc. Announces Company Name Change to Structure Therapeutics ShouTi Inc. announced today that it has secured $33 million in an oversubscribed financing, building on its $100 million Series B financing completed in October 2021. In addition, the company has completed dosing in its Phase 1 single ascending dose (SAD) study of GSBR-1290 for the…

In mid-June 2022, China successfully conducted a long-term animal study of a percutaneous ventricular assist device (pVAD). The animal study, which involved the pVAD running continuously for 10 days (with a designed duration of 5 days), has now been successfully completed. This achievement validates the long-term operational safety, reliability, and effectiveness of this pVAD product…

Shanghai, China & Brussels, Belgium – May 26, 2022 – Full-Life Technologies (“Full-Life”) today announced it completed a $37 million (USD) Series A financing round to advance the development of its radiopharmaceutical oncology product pipeline and its radiotechnology production platform. The financing round was led by Sequoia China, together with Yunion Healthcare Ventures, Junson Capital, CD…

December 21, 2021, Belgium and Shanghai, China: Full-Life Technologies (“Full-Life) today announced a $10 million seed round financing to advance the development of its broad pipeline of Precision Nuclear Medicines as well as its Nuclear Technology platform to address supply chain challenges in Nuclear Medicine. Chengwei Capital was the sole & lead investor and Full-Life was…

On December 4th, BayHelix held its second offline event of the year at the Tee Labs incubator in Zhangjiang, Shanghai. Themed “Bidding Farewell to the Old Year, Nurturing Body and Mind,” the event specially invited Leon Chen, a national-level referee and national bodybuilder, and Mark Tang, Managing Director of New York Health Capital, both of…

Tee Labs Incubatee: ShouTi Successfully Raises $100 Million in Series B Financing，Leveraging Advanced Computational and Structure-Based Drug Design Platform to Accelerate the Development of Life-Changing Medicines for Patients ShouTi Inc., a clinical-stage biopharmaceutical company, is dedicated to developing life-changing medicines for patients by leveraging advanced computational and structure-based technologies. The company announced on October 20th…

On September 16, Tee Labs, a biopharmaceutical innovation incubator managed by Shanghai Tee Labs Biotechnology, held its opening ceremony. Located in Shanghai’s Zhangjiang Hi-Tech Park, the incubator is dedicated to building an international biopharmaceutical innovation service platform. It provides startups with comprehensive support, including R&D facilities, supply services, operational management, investment, and financing, to co-create…

In 2021, TF Capital officially established and began operating the Tee Labs incubator and launched the first cohort (each cohort lasts 6 months) of its medical technology startup accelerator program. This accelerator aims to discover top entrepreneurs from around the world and provide outstanding startup projects with comprehensive support, including funding, space, business management, and…